Why the ADAURA study is a big step forward for NSCLC

Bookmark and Share
Published: 17 Jul 2020
Views: 668
Dr Luis Raez - Memorial Cancer Institute, Florida, USA

Dr. Luis Raez speaks to ecancer about adjuvant treatment for NSCLC.

He talks about the lack of breakthroughs in this area, the introduction of TKIs, and some the more important trials that have existed up until now.

Dr Raez then explains the ADAURA trial, using osimertinib, and why this is such a big step forwards to adjuvant therapy.